TQB 3912
Alternative Names: TQB-3912Latest Information Update: 05 Jun 2025
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II HER2 negative breast cancer
- Preclinical Solid tumours
Most Recent Events
- 16 May 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (PO) (NCT06851442)
- 28 Feb 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase I/II trial for HER2-negative breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second line therapy or greater) in China (PO, Tablet), in March 2025 (NCT06851442, TQB3912TQB3616Ib-II01)
- 24 Aug 2023 TQB 3912 is available for licensing in World as of 24 Aug 2023. https://www.cttq.com/en/